Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.
Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI's team of data scientists and engineers.
Tevogen CEO, Dr. Ryan Saadi, commented, 'Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. Tevogen.AI's vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at Tevogen.AI and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare.'
Strategic Partnerships:
Microsoft (Nasdaq: ): Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes.
Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen's AI models and enhance predictive accuracy.
Proprietary Tevogen.AI Technology:
PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments.
The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio's pipeline. To date, Tevogen.AI has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.
AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells.
AdapTcell is expected to significantly enhance Tevogen Bio's understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map.
Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results.
Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Tevogen.AI.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Old Dominion not changing course as downturn lingers
Not surprisingly, Old Dominion Freight Line said Wednesday it will continue its strategy of attempting to hold market share while raising yields through economic downturns. The approach has allowed it to consistently generate industry-leading margins. The less-than-truckload carrier said its book of business is off about 15% three years into a freight recession, a percentage it believes is on par with the rest of the industry. However, the company has been able to increase yields during this stretch, outperforming most in the space. Old Dominion's (NASDAQ: ODFL) revenue declined 6% y/y to $1.41 billion in the second quarter as tonnage fell 9.3% and revenue per hundredweight, or yield, increased 3.4% (5.3% higher excluding fuel surcharges). On a two-year-stacked comparison, the carrier's yield was 10.2% higher (excluding fuel). A 2.1% y/y decline in shipment weight was a modest tailwind to the yield metric in the quarter. Old Dominion's y/y tonnage comps ease in the back half of the year (negative-5% y/y and negative-8% y/y in the third and fourth quarters, respectively). However, the monthly sequential changes in tonnage during the second quarter still lagged historical trends by 200 to 300 basis points. Further, revenue per day was up less than 1% sequentially in the quarter when it normally increases 8.2%. Tonnage is down 8.5% y/y in July with revenue per day off 5.1% y/y. Both numbers represented a slight slowdown from the second-quarter declines. The carrier said the sequential tonnage change in July (from June) was about 100 bps better than normal. Management is calling for a 4% to 4.5% y/y increase in yield (excluding fuel) during the third quarter, which implies a roughly 1.5% sequential improvement. It said pricing on contract renewals continues to be positive and noted that the rate increases are accompanying more volume in some instances. The company reported a 74.6% operating ratio (inverse of operating margin), which was 270 bps worse y/y and just 80 bps better than the first quarter. That was shy of management's guidance for 100 bps of sequential improvement. (The carrier normally sees 300 to 350 bps of sequential margin improvement in the second quarter.) Cost per shipment was up 5.1% with revenue per shipment up just 1.2%, a 390-bp negative spread. Salaries, wages and benefits expenses (as a percentage of revenue) increased 210 bps y/y. A 4.8% decline in headcount didn't keep pace with the 7% drop in shipments. Depreciation and amortization expenses were 80 bps higher y/y. Old Dominion's OR normally sees no change to 50 bps of deterioration from the second to the third quarter. However, that move typically accompanies a 3% sequential increase in revenue, which is not occurring currently. If revenue remains flat throughout the quarter, the carrier will likely see 80 to 120 bps of margin degradation, implying a 75.6% OR (at the midpoint), or 290 bps worse y/y The carrier also faces some headwinds across multiple expense lines. Benefits costs are up and the company implements an annual wage increase every September. It also called out recent losses on equipment sales as it modestly trims the fleet. Truckload carriers selling two-year-old tractors have been booking gains, but Old Dominion is trying to move 10-year-old daycabs with more than one million miles. The company is also carrying excess capacity (and additional costs) as it awaits an eventual market turn. As such, its overhead costs represented 22% of revenue in the second quarter compared to just 17% in 2022 — a much stronger demand environment. The company's high-fixed-cost network should again see operating leverage as revenue increases. Old Dominion saw a 60% incremental operating margin in the second quarter (as compared to the first quarter). It normally sees 35% to 40% incremental margins coming out of downturns. Old Dominion reported second-quarter earnings per share of $1.27 ahead of the market open on Wednesday. The result was a penny light of the consensus estimate and 21 cents lower y/y. A decline in net interest income was nearly a 2-cent drag compared to the year-ago quarter. Shares of ODFL were down 8.7% at 12:23 p.m. EDT on Wednesday compared to the S&P 500, which was up 0.3%. Shares of ArcBest (NASDAQ: ARCB) were also under pressure, down 11.1%, after reporting second-quarter results light of expectations earlier in the day. More FreightWaves articles by Todd Maiden: First look: ArcBest Q2 earnings Landstar reports trucking revenue growth for first time in nearly 3 years Losses mount at Pamt, TL unit posts 112.5% OR The post Old Dominion not changing course as downturn lingers appeared first on FreightWaves.
Business Wire
6 minutes ago
- Business Wire
Fujifilm's Business Innovation and Imaging Divisions to Exhibit Broad Range of Print Solutions at IPIC 2025
VALHALLA, N.Y. & HANOVER PARK, Ill.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Business Innovation and Imaging Divisions, jointly announce their presence at the upcoming International Print and Imaging Conference (IPIC), being held August 3-7, 2025, in Las Vegas. The two divisions will be onsite demonstrating Fujifilm's full-circle offerings in the imaging life cycle – from initial image capture to final printed output – which empower IPI Network Members to gain the latest product knowledge to maximize their business potential in the independent retail space. Fujifilm's Business Innovation Division will feature its REVORIA PRESS™ SC285S (SC285S) onsite at IPIC. Bringing the high-end capabilities of Fujifilm's flagship REVORIA PRESS™ PC1120 digital press to a mid-range printing press, the SC285S is equipped with a specialty toner station 1 in addition to its four-color toners, enabling five-color printing in one pass. SC285S achieves a compact footprint through Fujifilm's newly developed Vertical Toner Development Technology, which transports developer from bottom to top against gravity, significantly reducing the size of each development unit, and in turn enabling five-color printing without increasing the machine size. With the addition of its specialty colors, the SC285S delivers richer, more vibrant prints with smoother gradients, to satisfy a wide variety of customer needs. Its versatility creates potential for unique and customizable projects that were not previously possible from a press of this size. 'There's no denying the power of print,' said Yuji Oki, general manager, FUJIFILM North America Corporation, Business Innovation Division. 'Take a look around you, the printed image is everywhere. In our homes, places of business, schools – the printed image is key to how we communicate with the world. At IPIC 2025, we are celebrating our commitment to print by displaying and demonstrating our latest print technologies so our customers can continue to 'Make More' with Fujifilm.' Also featured in the IPIC booth will be samples of output from the Revoria press after lamination with Fujifilm's latest partner, Skandacor, whose LAMpro Cheetah S15 Photo product combines laminate film technology with high-quality digital prints to create photos that mirror the look, feel and weight of traditional Silver Halide photos. Samples of prints from Fujifilm's SC285S that have this special laminate applied will be available for review in Fujifilm's IPIC booth. Additionally, Fujifilm's Andrew Gunn, director of product solutions and enablement for the Americas, will lead a conversation on 'Digital Print in the New Age' at IPIC, as part of their educational series. This presentation is scheduled for August 5 at 11:00 Pacific time. Fujifilm's Imaging Division will also be onsite at IPIC to share its latest innovations in photo printing, namely the recently announced FUJIFILM Frontier DX400W (DX400W) compact inkjet printer. The latest addition to Fujifilm's Frontier printer lineup, DX400W boasts improvements in printing output, including the addition of two new ink colors, as well as faster image processing/printing times and a smaller overall footprint than its predecessor, DX100. Also onsite will be the group's instax™ line of instant cameras and smartphone printers, as well as products from Fujifilm's Personalized Photo Products Group, which produces a wide variety of photo solutions, including photo prints and cards, photo books, wall art, drinkware, home and office décor and accessories, ornaments, and more. Rounding out Fujifilm's presence at IPIC will be key products from the company's line of professional-grade FUJINON binocular products. 'With our beginnings over 90 years ago as a film company, imaging is a core part of our DNA,' said Bing Liem, division president, FUJIFILM North America Corporation, Imaging Division. 'IPIC is not only the perfect place to demonstrate Fujifilm's commitment to the printed image, but to our independent photo retailers as well. They play a vital role in connecting with our imaging consumers, and their technical expertise and passion enable them to guide our customers in making well-informed decisions about their imaging needs." Fujifilm is proud to be the longest-term Premium Platinum sponsor in IPI's history, with a partnership spanning well over 20 years, demonstrating its continued dedication to supporting the print medium. FUJIFILM North America Corporation's Business Innovation and Imaging Divisions will be onsite at IPIC 2025, Booth # 305, at Red Rock Resort and Hotel in Las Vegas. For more information about Fujifilm's print solutions, visit For more information about Fujifilm's imaging solutions, visit About Fujifilm FUJIFILM North America Corporation, a marketing subsidiary of FUJIFILM Holdings America Corporation, consists of six operating divisions. The Imaging Division provides consumer and commercial photographic products and services, including silver halide consumables; inkjet consumables; digital printing equipment, along with service and support; personalized photo products fulfillment; film; one-time-use cameras; and the popular INSTAX® line of instant cameras, smartphone printers, instant film, and accessories. The Electronic Imaging Division markets its GFX System and X Series lines of mirrorless digital cameras, lenses, and accessories to provide a variety of content creation solutions for both still and moving imagery. The Optical Devices Division provides optical lenses for the broadcast, cinematography, closed circuit television, videography, and industrial markets, and also markets binoculars and other optical imaging solutions. The Business Innovation Division offers a full lineup of digital print and toner technologies focused on enabling the digital transformation of businesses and print shops with its offerings of multifunction printers, digital inkjet presses, production toner printers, software, and more. The Industrial Products Division delivers new products derived from Fujifilm technologies including data storage tape products, including OEM and FUJIFILM Ultrium LTO cartridges, desalination solutions, microfilters and gas separation membranes. For more information, please visit go to to follow Fujifilm on X, or go to to Like Fujifilm on Facebook. FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here. FUJIFILM, REVORIA PRESS, and instax are trademarks of FUJIFILM Corporation and its affiliates. © 2025 FUJIFILM North America Corporation and its affiliates. All rights reserved. 1 Clear, pink, gold, silver and white for specialty toners. Availability of gold, silver and white will be announced soon.
Yahoo
34 minutes ago
- Yahoo
Why Costco (COST) is a Top Dividend Stock to Buy in August
Costco Wholesale Corporation (NASDAQ:COST) is included among the 10 Best Dividend Stocks to Buy in August. A customer in a warehouse aisles, browsing the wide range of branded and private-label products. Costco Wholesale Corporation (NASDAQ:COST), a top membership-based warehouse retailer known for selling bulk items, posted strong sales results for June. According to a recent company update, Costco Wholesale reported a 5.8% increase in total comparable sales for the month. US comparable sales alone grew by 4.7%. Monthly net sales reached $26.44 billion, marking an 8% increase from $24.48 billion in the same period a year earlier. When excluding the effects of fuel prices and foreign exchange, total comparable sales rose 6.2%, while US sales adjusted for those factors were up 5.5%. The company continues to grow steadily despite its already massive size. For the current fiscal year, which wraps up around late August, the company plans to add a net total of 24 new warehouse locations. Looking ahead, the leadership team is targeting the opening of 25 to 30 new stores annually, with significant growth potential still available in both the US and global markets. Costco Wholesale Corporation (NASDAQ:COST) is a solid dividend payer. On July 16, the company declared a quarterly dividend of $1.30 per share, having raised it by 12% in April. This marked the company's 21st consecutive year of dividend growth, which makes COST one of the best dividend stocks. COST has a dividend yield of 0.56%, as of July 28. While we acknowledge the potential of COST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
